Navigation Links
Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports
Date:6/28/2010

I Research's team of industry experts. GBI Research finds that the gastrointestinal disorder therapeutics market will decline during the period 2009-2016. This decline is primarily driven by the negative growth of gastroesophageal reflux disease (GERD) therapeutics market which is attributed to loss of drug patents and entry of generics. However, other key gastrointestinal disorders such as crohn's disease and irritable bowels syndrome therapeutics market will continue to grow due to strong late stage pipeline that will address the unmet needs. The global gastrointestinal disorder therapeutics market is a highly fragmented market and big players are facing stiff competition. The forthcoming patent expiries of major drugs have increased the competition, driving the consolidation further. The increasing pressure has also driven companies to enter into licensing agreements. This allows companies to expand product portfolio and improve their competitive positions in the market.

    Scope

    - The scope of this report includes:
    - Annualized market data for the gastrointestinal disorder
      therapeutics market from 2001 to 2009, forecast forward to 2016
    - Analysis of the leading therapeutic segments. These include
      crohn's disease, ulcerative colitis, irritable bowel syndrome, and
      gastroesophageal reflux disease.
    - Analysis of the gastrointestinal disorder therapeutics market in
      the leading geographies of the world, which include the US, the UK,
      Germany, France, Italy, Spain, and Japan
    - Market characterization of the gastrointestinal disorder
      therapeutics market including market size, annual cost of therapy, and
      treatment usage patterns
    - Key drivers and barriers that have a significant impact on the
      market
    - Coverage of pipeline molecules in various phases of drug
      development
    - Competitive benchmarking of leading companies. The key companies
      studied in this report are AstraZen
'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
2. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
3. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
7. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
8. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. SleepQuest Raises Awareness of Sleep Disorders
11. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... GLASGOW, Scotland , September 17, 2014 ... a new mode of action from a ... a decade  MGB Biopharma, a ... of anti-infectives, announces today that it has ... of its lead antibacterial, MGB-BP-3, against a ...
(Date:9/16/2014)... September 16, 2014 “Nature has developed, ... features that we desire in optical design,” said Joseph ... State University. “As we explore surfaces and structures at ... lessons were presented in San Diego in August during ... in Nature ” chaired by Shaw and Rongguang Liang ...
(Date:9/16/2014)... WASHINGTON, D.C., September 16, 2014 --The emerging field ... portable to the next level, enabling the construction ... highly efficient devices, individual molecules would take on ... and transistors. , A team of researchers from ... potential candidate for use in small-scale electronics: a ...
(Date:9/16/2014)... 16, 2014 Cardioxyl Pharmaceuticals, Inc. ... been shown to be effective in animal models following ... to intravenous infusions that could pave the way for ... presented yesterday at the Heart Failure Society of America,s ... Las Vegas . The research, ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... Summary: Genmab Reports Results for the First Three Months of ... today results for the three month period ended March 31, ... revenues were DKK 167 million (approx. USD 36 million) for ... Genmab recognized,revenues of DKK 80 million (approx. USD 17 million)., ...
... Md., May 28 Novavax, Inc. (Nasdaq:,NVAX) a clinical-stage ... Chief Executive Officer, will be presenting at the,FBR Capital ... on,May 29, 2008 at The Grand Hyatt Hotel in ... company,s strategy, research and development progress. A,link to the ...
... NanoLogix, Inc. (Pink,Sheets: NNLX) a nano-biotechnology company ... personnel will showcase company technology at booth 1304 ... June 1-5 2008. The ASM,meeting is the world,s ... Dr. Sergey Gazenko and CEO Bret Barnhizer.,Exhibition information ...
Cached Biology Technology:Genmab Announces 2008 First Quarter Results 2Genmab Announces 2008 First Quarter Results 3Genmab Announces 2008 First Quarter Results 4NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update 2
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
Breaking Biology News(10 mins):Coral growth rate plummets in 30-year comparison 2Sharks' skin has teeth in the fight against hospital superbugs 2Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... URBANA A recent research study has shown that ... of food due to resource constraints, can lead to ... pregnancy. "Prior studies have shown that women ... experience health complications," said Craig Gundersen, a University of ...
... CORVALLIS, Ore. Scientists are a valuable and ... report, but too often do an inadequate job of ... a factual, non-technical, credible and neutral format. An ... establishment of "marine reserves" off the California coast offers ...
... 2010 - An article in the current issue of Global ... a perennial grass, could effectively reduce our dependence on fossil fuels, ... tool that models the future global climate, researchers predict that the ... natural vegetation will be paid back by Miscanthus within ...
Cached Biology News:Food insecurity increases risk of weight gain and complications during pregnancy 2Scientists need to be more proactive, effective at public communication 2Scientists need to be more proactive, effective at public communication 3
... is a personal desktop unit ideal for use ... , Rotation speed set at 12 rpm ... C , Bottle capacity of four 35 ... ml conical ,plastic bottles , Consistent, repeatable ...
... The SC250 Express is the latest edition ... SC250 Express has an extra large diameter ... The digital display panel allows precise setting ... Large chamber for handling large quantities and ...
... a no-frills, basic SpeedVac concentrator designed for ... this unit still features a standard Teflon ... of time and heat. It is designed ... a wide variety of different rotors for ...
... RC Maxi MB (for aqueous, other low ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
Biology Products: